Nanomedicine: Nanotechnology, Biology and Medicine
Volume 4, Issue 2 , Pages 115-120 , June 2008

Preparation and characterization of insulin nanoparticles using chitosan and its quaternized derivatives

  • Akbar Bayat, PhD

      Affiliations

    • Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran
    • Cosar Pharmaceutical Company, Tehran, Iran
    • ,
  • Bagher Larijani, MD

      Affiliations

    • Endocrinology Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
    • ,
  • Shahin Ahmadian, PhD

      Affiliations

    • Institute of Biochemistry and Biophysics, Tehran University, Tehran, Iran
    • ,
  • Hans E. Junginger, PhD

      Affiliations

    • Department of Pharmaceutical Technology, Leiden/Amsterdam Center for Drug Research, Leiden, The Netherlands
    • Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand
    • ,
  • Morteza Rafiee-Tehrani, PhD

      Affiliations

    • Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran
    • Corresponding Author InformationCorresponding author. School of Pharmacy, Tehran University of Medical Sciences, P.O. Box 14395/459 Tehran Postal Code 14, Iran.

Received 18 October 2007 ,Accepted 31 January 2008.

References 

  1. Owens DR, Zinman B, Bolli G. Alternative routes of insulin delivery. Diab Med. 2003;20:886–898
  2. Saffran M, Pansky B, Budd GC, Williams FE. Insulin and the gastrointestinal tract. J Control Rel. 1997;46:89–98
  3. Mesiha M, Plakogiannis F, Vejosoth S. Enhanced oral absorption of insulin from desolvated fatty acid-sodium glycocholate emulsions. Int J Pharm. 1994;111:213–216
  4. Radwant MA, Aboul-Enein HY. The effect of oral absorption enhancers on the in vivo performance of insulin-loaded poly(ethylcyanoacrylate) nanospheres in diabetic rats. J Microencapsul. 2002;19:225–235
  5. Morishita I, Morishita M, Takayama K, Machida Y, Nagai T. Hypoglycemic effect of novel oral microspheres of insulin with protease inhibitor in normal and diabetic rats. Int J Pharm. 1992;79:9–16
  6. Bernkop-Schnurch A. The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J Control Rel. 1998;52:1–16
  7. Takeuchi H, Yamamoto H, Niwa T, Hino T, Kawashima Y. Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes. Pharm Res. 1996;13:896–901
  8. Asada H, Douen T, Waki M, Adachi S, Fujita T, Yamamoto A, et al. Absorption characteristics of chemically modified-insulin derivatives with various fatty acids in the small and large intestine. J Pharm Sci. 1995;84:682–687
  9. Florence AT, Hillery AM, Hussain N, Jani PU. Nanoparticles as carriers for oral peptide absorption: studies on particle uptake and fate. J Control Rel. 1995;36:39–46
  10. Couvreur P, Puisieux F. Nano- and microparticles for the delivery of polypeptides and proteins. Adv Drug Del Rev. 1993;10:141–162
  11. Vila A, Sanchez A, Tobio M, Calvo P, Alonso MJ. Design of biodegradable particles for protein delivery. J Control Rel. 2002;78:15–24
  12. Damage C, Vonderscher J, Marbach P, Pinget M. Poly (alkylcyanoacrylate) nanocapsules as a delivery system in the rat for octreotide, a long-acting somatostatin analogue. J Pharm Pharmacol. 1997;49:949–954
  13. Kreuter J. Nanoparticles. In:  Kreuter J editors. Colloidal drug delivery systems. NewYork: Marcel Dekker; 1994;p. 219–342
  14. Mao H, Roy K, Troung-Le VL, Janes KA, Lin KY, Wang Y, et al. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Control Rel. 2001;70:399–421
  15. Mao S, Bakowsky U, Kissel T. Self assembled polyelectrolyte nanocomplexes between chitosan derivatives and insulin. J Pharm Sci. 2006;95:1035–1048
  16. Jintapattanakit A, Junyaprasert VB, Mao S, Sitterberg J, Bakowsky U, Kissel T. Peroral delivery of insulin using chitosan derivatives: a comparative study of polyelectrolyte nanocomplexes and nanoparticles. Int J Pharm. 2007;342:240–249
  17. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Rel. 2004;100:5–28
  18. Thanou M, Verhoef JC, Junginger HE. Chitosan and its derivatives as intestinal absorption enhancers. Adv Drug Del Rev. 2001;50:S91–S101
  19. Curti E, de Britto D, Campana-Filho SP. Methylation of chitosan with iodomethane: effect of reaction conditions on chemoselectivity and degree of substitution. Macromol Biosci. 2003;3:571–576
  20. Avadi MR, Zohuriaan-mehr MJ, Younessi P, Amini M, Rafiee-Tehrani M, Shafiee A. Optimized synthesis and characterization of N-triethyl chitosan. J Bioact Compat Polym. 2003;18:469–479
  21. Bayat A, Sadeghi AMM, Avadi MR, Amini M, Majlesi R, Junginger HE, et al. Synthesis of N,N-dimethyl N-ethyl chitosan as a carrier for oral delivery of peptide drugs. J Bioact Compat Polym. 2006;21:433–444
  22. Fernandez-Urrusuno R, Calvo P, Remunan-Lopez C, Villa-Jato JL, Alonso M. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm Res. 1999;16:1576–1581
  23. Brange J. Galenics of insulin. In: The physio-chemical and pharmaceutical aspects of insulin and insulin preparations. Berlin: Springer-Verlag; 1987;p. 1–103
  24. Couvreur P, Barratt G, Fattal E, Legrand P, Vauthier C. Nanocapsule technology: a review. Crit Rev Ther Drug Carrier Syst. 2002;19:99–134
  25. Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci. 1997;63:125–132
  26. Carino GP, Mathiowits E. Oral insulin delivery. Adv Drug Deliv Rev. 1999;35:249–257
  27. Clark MA, Jepson MA, Hirst BH. Exploiting M cells for drug and vaccines delivery. Adv Drug Deliv Rev. 2001;50:81–106
  28. Van de weert M, Hennink WE, Jiskoot W. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm Res. 2000;17:1159–1167
  29. Sakuma S, Ohshima H, Kondo T. Charge distribution in poly(N,N-l-lysinediylterephthaloyl) microcapsules membrane. J Colloid Interface Sci. 1998;133:253–256
  30. Janes KA, Fresneau MP, Marazuela A, Fabra A, Alonso MJ. Chitosan nanoparticles as delivery systems for doxorubicin. J Control Rel. 2001;73:255–267
  31. Fresta M, Puglisi G, Giammona G, Cavallaro G, Micali N, Furneri PM. Pefloxacin mesilate and ofloxacin-loaded polyethylcyanoacrylate nanoparticles: characterization of the colloidal drug carrier formulation. J Pharm Sci. 1995;84:895–902

 This research was supported by a grant from the research council of Tehran University of Medical Sciences, and COSAR Pharmaceutical Company.

PII: S1549-9634(08)00004-X

doi: 10.1016/j.nano.2008.01.003

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 4, Issue 2 , Pages 115-120 , June 2008

Article Tools

* Image Usage & Resolution